Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
IGF-1 DES (1-3)
Overview
IGF-1 DES (1-3) is a truncated analogue of insulin-like growth factor 1 lacking the first three N-terminal amino acids (glycine-proline-glutamate). This structural modification prevents binding to IGF binding proteins in serum, resulting in a shorter half-life but significantly increased potency at the IGF-1 receptor compared to native IGF-1.
Mechanism of Action
The peptide is hypothesized to promote localized muscle hypertrophy and tissue repair through enhanced receptor activation in target tissues.
Research Summary & Key Findings
No controlled clinical trials have been published in peer-reviewed journals. Evidence is limited to preclinical cell culture and animal models demonstrating increased myoblast proliferation and differentiation. This agent remains unregulated and its safety and efficacy in humans have not been established through formal investigation.
Clinical Status
IGF-1 DES (1-3) is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.
Administration Routes
References
Primary literature
- PubMed: "IGF-1 DES"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "IGF-1 DES"
Registered interventional and observational studies, including status and phase.
- PubChem: "IGF-1 DES"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Performance
Melanotan II
Research PhaseA synthetic cyclic analog of alpha-melanocyte stimulating hormone (alpha-MSH) that non-selectively activates melanocorti...
View detailsIGF-1 LR3 (Long-Arg3)
Research PhaseIGF-1 LR3 is a synthetic analogue of insulin-like growth factor 1 with an N-terminal extension of 13 amino acids and a s...
View detailsMGF (Mechano Growth Factor)
Research PhaseMechano Growth Factor is a splice variant of the IGF-1 gene expressed in response to mechanical stress on muscle tissue....
View detailsPEG-MGF
Research PhasePEG-MGF is a pegylated derivative of Mechano Growth Factor designed to extend systemic half-life through the addition of...
View detailsNo lawful pathway today
IGF-1 DES (1-3) is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so there is nothing for us to sell you here and no consultation to book. That can change: eight peptides moved back to a lawful pathway in February 2026.
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Join the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.